File(s) under permanent embargo

Reason: for access to this file, please contact T. Schepers at

data WIFI trial; wound infection following implant removal

posted on 13.03.2018, 08:45 by F.R.K. Sanders, T. Schepers, M. Backes, S.A. Dingemans, M.G.W. Dijkgraaf, H.R. van den Berg, B. van Dijkman, J.M. Hoogendoorn, P. Joosse, E.D. Ritchie, W.H. Roerdink, J.P.M. Schots, N.L. Sosef, I.J.B. Spijkerman, B.A. Twigt, A.H. van der Veen, R.N. van Veen, J. Vermeulen, D.I. Vos, J. Winkelhagen, J.C. Goslings

Multicenter, double-blind, randomized clinical trial including 500 patients aged 18 to 75 years with previous surgical treatment for fractures below the knee who were undergoing removal of orthopedic implants from 19 hospitals (17 teaching and 2 academic) in the Netherlands (November 2014-September 2016), with a follow-up of 6 months (final follow-up, March 28, 2017). Exclusion criteria were an active infection or fistula, antibiotic treatment, reimplantation of osteosynthesis material in the same session, allergy for cephalosporins, known kidney disease, immunosuppressant use, or pregnancy.


A single preoperative intravenous dose of 1000 mg of cefazolin (cefazolin group, n = 228) or sodium chloride (0.9%; saline group, n = 242).


Primary outcome was SSI within 30 days as measured by the criteria from the US Centers for Disease Control and Prevention. Secondary outcome measures were functional outcome, health-related quality of life, and patient satisfaction.


Among 477 randomized patients (mean age, 44 years [SD, 15]; women, 274 [57%]; median time from orthopedic implant placement, 11 months [interquartile range, 7-16]), 470 patients completed the study. Sixty-six patients developed an SSI (14.0%): 30 patients (13.2%) in the cefazolin group vs 36 in the saline group (14.9%) (absolute risk difference, -1.7 [95% CI, -8.0 to 4.6], P = .60).

For access to the dataset please contact author


Retention period


Research priority area

  • Infection & Immunity


Academic Medical Center (AMC)